Physician profile
Thottathil Gopan
NPI 1023148939
$7,679.25
in general payments reported to CMS, 2019-2025
35 companies · $1,556 in 2025
The $1,556 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,773 · 2020: $43.07 · 2021: $547 · 2022: $601 · 2023: $1,862 · 2024: $1,297 · 2025: $1,556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,695 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,695.49 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,187.37 | 2019-2025 | |
| Insulet Corporation | $924.88 | 2019-2025 | Omnipod |
| Novo Nordisk INC | $903.34 | 2019-2025 | Wegovy, Ozempic |
| Abbott Laboratories | $597.29 | 2019-2024 | Freestyle Libre 3 |
| Medtronic, INC. | $406.41 | 2023-2025 | Inpen Smart Insulin Delivery System, Minimed 780g |
| Dexcom, INC. | $367.30 | 2019-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $351.32 | 2023 | Tepezza |
| Tandem Diabetes Care, INC. | $264.10 | 2023-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Beta Bionics, INC. | $260.39 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Madrigal Pharmaceuticals | $239.29 | 2025 | Rezdiffra |
| Alexion Pharmaceuticals, INC. | $230.18 | 2019-2021 | |
| Amgen INC. | $214.25 | 2023-2025 | Evenity |
| Sanofi-Aventis U.S. LLC | $198.69 | 2019 | |
| Xeris Pharmaceuticals, INC. | $190.50 | 2024-2025 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.72 | 2019-2023 | Jardiance |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $140.91 | 2019-2023 | Afrezza |
| Sequel Med Tech, LLC | $134.32 | 2025 | Twiist |
| Ascendis Pharma Endocrinology INC | $124.99 | 2025 | Yorvipath |
| Cequr Corporation | $117.20 | 2023 | Cequr Simplicity |
| Lilly USA, LLC | $107.95 | 2025 | Mounjaro |
| Janssen Pharmaceuticals, INC | $99.86 | 2019 | |
| Endo Pharmaceuticals INC. | $78.88 | 2019 | |
| Shire North American Group INC | $64.17 | 2019 | |
| Abbvie INC. | $62.35 | 2019 | |
| Antares Pharma, INC. | $46.77 | 2019-2020 | |
| Amarin Pharma, INC. | $35.70 | 2019 | |
| Ibsa Pharma INC. | $34.06 | 2019 | |
| Eisai INC. | $26.45 | 2019 | |
| Ascensia Diabetes Care US INC. | $21.73 | 2025 | |
| Becton, Dickinson and Company | $21.06 | 2019 | |
| Ucb, INC. | $19.78 | 2019 | |
| Vivus LLC | $18.91 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $11.54 | 2019 | |
| Lifescan, INC. | $11.45 | 2019 | |
| Medtronic Minimed, INC. | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thottathil Gopan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.